miRNAs in chronic hepatitis B: From potential biomarkers to therapeutic targets

V. Loukachov

miRNAs in chronic hepatitis B: From potential biomarkers to therapeutic targets

Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

Abstract

In chapter 2 we showed in a long term follow up of five years, that HBsAg-loss over time is not influenced by either a combination of peg-IFN and adefovir or tenofovir treatment in CHB patients. Although low baseline HBsAg levels can predict HBsAg-loss irrespective of treatment allocation.
In chapter 3 we identified several differentially expressed miRNAs in plasma

Original language	English
Qualification	Doctor of Philosophy
Awarding Institution	University of Amsterdam
Supervisors/Advisors	Kootstra, Neeltje, Supervisor Beuers, Ulrich, Supervisor Reesink, Hendrik, Co-supervisor
Award date	13 Sept 2023
Print ISBNs	9789464694826
Publication status	Published - 2023

Access to Document

https://pure.uva.nl/ws/files/134861419/Front_matter.pdf

Cite this

@phdthesis{3bc7140b78e349ab9b2be82a078ff15f,

title = "miRNAs in chronic hepatitis B: From potential biomarkers to therapeutic targets",

abstract = "In chapter 2 we showed in a long term follow up of five years, that HBsAg-loss over time is not influenced by either a combination of peg-IFN and adefovir or tenofovir treatment in CHB patients. Although low baseline HBsAg levels can predict HBsAg-loss irrespective of treatment allocation.In chapter 3 we identified several differentially expressed miRNAs in plasma",

author = "V. Loukachov",

year = "2023",

language = "English",

isbn = "9789464694826",

type = "Phd-Thesis - Research and graduation internal",

school = "University of Amsterdam",

}

TY - THES

T1 - miRNAs in chronic hepatitis B

T2 - From potential biomarkers to therapeutic targets

AU - Loukachov, V.

PY - 2023

Y1 - 2023

N2 - In chapter 2 we showed in a long term follow up of five years, that HBsAg-loss over time is not influenced by either a combination of peg-IFN and adefovir or tenofovir treatment in CHB patients. Although low baseline HBsAg levels can predict HBsAg-loss irrespective of treatment allocation.In chapter 3 we identified several differentially expressed miRNAs in plasma

AB - In chapter 2 we showed in a long term follow up of five years, that HBsAg-loss over time is not influenced by either a combination of peg-IFN and adefovir or tenofovir treatment in CHB patients. Although low baseline HBsAg levels can predict HBsAg-loss irrespective of treatment allocation.In chapter 3 we identified several differentially expressed miRNAs in plasma

M3 - Phd-Thesis - Research and graduation internal

SN - 9789464694826

ER -